WESTBOROUGH, Mass.--(BUSINESS WIRE)-- RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major ...
Marlborough-based biotech RXi Pharmaceuticals ended 2017 with $3.6 million in cash, about a third of what if had at the end of 2016, according to a financial statement released by the company Monday.
On August 1st RXi Pharmaceuticals (RXII) issued a press release announcing positive results from their RXI-109-1501 Phase I/II trial for retinal scarring. The primary outcome for the trial was to ...
Westborough-based RXi Pharmaceuticals has signed an agreement with a British company to distribute RXi’s clinical-stage dermal scarring drug in the European Union ahead of regulatory approval. RXi ...
We are initiating coverage of RXi Pharmaceuticals Corp (RXII) with a $20.00 price target based on our estimates for a 2023 launch of RXI-109 and a 2022 launch of Samcyprone, both through the efforts ...
WESTBOROUGH, Mass.--(BUSINESS WIRE)-- RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major ...
RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced the appointment of Dr. Jeannette Graf and Dr. Leroy Young to its Scientific Advisory Board. The addition of these two highly esteemed ...
MARLBOROUGH, Mass., June 7, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical ...
Financing Led by OPKO Health, Inc. and Frost Gamma Investments Trust, a Trust Controlled by Phillip Frost, M.D. WESTBOROUGH, Mass. & MIAMI--(BUSINESS WIRE)-- RXi Pharmaceuticals Corporation (OTC: RXII ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results